InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Browse the detailed record of transactions filed by BOBO DONALD E JR, Corporate Vice President, Strategy & Corporate Development. Director active across 1 companies, notably Edwards Lifesciences Corp. Cumulatively, 40 filings have been published. The latest transaction was disclosed on 11 May 2026 — Levée d'options. Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations40 total
013,457 shares0
Common Stock
SEC:0001225208-26-005171·
013,457 shares0
Common Stock
SEC:0001225208-26-005171:0·
US$573,60111,340 shares@ US$50.58210.0012% mcap17.9% of flow
Common Stock
SEC:0001225208-26-000378·
€573,60111,340 shares@ €50.58210.0012% mcap7.9% of flow
Common Stock
SEC:0001225208-26-000378:0·
US$577,87511,340 shares@ US$50.9590.0012% mcap18.1% of flow
Common Stock
SEC:0001225208-25-009841·
€577,87511,340 shares@ €50.9590.0012% mcap7.9% of flow
Common Stock
SEC:0001225208-25-009841:0·
€227,2636,725 shares@ €33.79380.0005% mcap3.1% of flow
Common Stock
SEC:0001225208-22-008029:0·
€158,5211,743 shares@ €90.94740.0003% mcap2.2% of flow
Common Stock
SEC:0001225208-22-007134:0·
€57,605604 shares@ €95.37240.0001% mcap0.8% of flow
Common Stock
SEC:0001225208-22-006816:0·
03,775 shares0
Common Stock
SEC:0001225208-22-006578:0·
€221,30811,050 shares@ €20.02790.0004% mcap3.0% of flow
Common Stock
SEC:0001225208-22-005741:0·
€218,31211,050 shares@ €19.75680.0004% mcap3.0% of flow
Common Stock
SEC:0001225208-22-004575:0·
€210,63211,050 shares@ €19.06180.0004% mcap6.6% of flow
Common Stock
SEC:0001225208-22-001971·
€210,63211,050 shares@ €19.06180.0004% mcap2.9% of flow
Common Stock
SEC:0001225208-22-001971:0·
01,000 shares0
Common Stock
SEC:0001225208-22-001213·
01,000 shares0
Common Stock
SEC:0001225208-22-001213:0·
€212,91211,050 shares@ €19.2680.0004% mcap6.7% of flow
Common Stock
SEC:0001225208-21-014810·
€212,91211,050 shares@ €19.2680.0004% mcap2.9% of flow
Common Stock
SEC:0001225208-21-014810:0·
€208,08411,050 shares@ €18.83110.0004% mcap6.5% of flow
Common Stock
SEC:0001225208-21-013644·
€208,08411,050 shares@ €18.83110.0004% mcap2.9% of flow
Common Stock
SEC:0001225208-21-013644:0·
€208,00411,050 shares@ €18.82390.0004% mcap6.5% of flow
Common Stock
SEC:0001225208-21-013067·
€208,00411,050 shares@ €18.82390.0004% mcap2.9% of flow
Common Stock
SEC:0001225208-21-013067:0·
€203,32311,050 shares@ €18.40030.0004% mcap6.4% of flow
Common Stock
SEC:0001225208-21-012285·
€203,32311,050 shares@ €18.40030.0004% mcap2.8% of flow
Common Stock
SEC:0001225208-21-012285:0·
€203,15511,050 shares@ €18.3850.0004% mcap6.3% of flow
Common Stock
SEC:0001225208-21-011316·
25 of 40 declarations
About BOBO DONALD E JR
Donald E. Bobo, Jr. is a Corporate Vice President at Edwards Lifesciences, where he leads corporate strategy and corporate development. Company disclosures indicate that he has served in this role since 2007 and also has executive responsibility for key heart failure initiatives, as well as the U.S. healthcare solutions and commercial services team. His career spans more than 35 years in the medical technology and healthcare industries. Within Edwards, Bobo has held several important operating roles. He has been involved in developing the company’s Transcatheter Mitral and Tricuspid Therapies (TMTT) business, served as Vice President and General Manager of the Surgical business, and overseen global valve manufacturing operations. Taken together, these positions point to a blend of strategic leadership, business-building experience, and operational oversight across both established and emerging therapy areas. His background suggests deep familiarity with regulated healthcare markets, product commercialization, and manufacturing execution. Before joining Edwards in 1995, he held positions of increasing responsibility at American Hospital Supply, Baxter Healthcare Corporation, and InnerSpace Medical. That earlier experience provided a foundation in the broader healthcare supply and device ecosystem and helped shape a career path that moved from operational and commercial roles into enterprise-level leadership. Beyond Edwards, Bobo has also been active in the wider medtech and life sciences community. He serves on the boards of egnite and the Advanced Medical Technology Association (AdvaMed), and he previously served as a board member and executive committee chair of the California Life Sciences Association. He has also been engaged with the American Heart Association. These affiliations reinforce a profile centered on cardiovascular innovation, industry advocacy, and cross-sector leadership. Overall, his career reflects long-term stewardship of growth initiatives, business transformation, and operational discipline within a leading U.S. medical technology company.
